John Hyngstrom

3.1k citations

68 papers · 1.3k indexed · h-index 19

Impact in

Oncology top 5%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Colorectal Cancer Surgical Treatments
Immunology top 10%
- Immunotherapy and Immune Responses

Papers in

Oncology 53
- Cutaneous Melanoma Detection and Management 26
- CAR-T cell therapy research 24
- Cancer Immunotherapy and Biomarkers 22
Immunology 20
- Immunotherapy and Immune Responses 18

Co-authors: Robert H.I. Andtbacka Russell S. Richardson Barry W. Feig George J. Chang Yan Xing Miguel A. Rodrı́guez-Bigas Janice N. Cormier John M. Skibber
Journals: Journal of Clinical Oncology (8 papers)Annals of Oncology (6 papers)Melanoma Research (6 papers)Journal of Surgical Oncology (5 papers)American Journal of Physiology-Heart and Circulatory Physiology (4 papers)
Partner nations: United States Australia Switzerland

In The Last Decade

John Hyngstrom

62 papers receiving 1.3k citations

Peers

Countries citing papers authored by John Hyngstrom

Since Specialization

Citations

This map shows the geographic impact of John Hyngstrom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Hyngstrom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Hyngstrom more than expected).

Fields of papers citing papers by John Hyngstrom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Hyngstrom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Hyngstrom. The network helps show where John Hyngstrom may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John Hyngstrom, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John Hyngstrom Line = papers co-authored together John Hyngstrom links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas Clinical Cancer Research ·Kevin J. Harrington, Stéphane Champiat, Joshua Brody, Byoung Chul Cho, Emanuela Romano, Talia Golan, John Hyngstrom, James Strauss, David Y. Oh, Aron Popovtzer, Carlos Gomez‐Roca, Ruth Perets, Sung‐Bae Kim, Deborah J. Wong, Steven Powell, Anuradha Khilnani, Thomas Jemielita, D. Barry Starr, Runchen Zhao, Matthew Ingham	2025	10
2	1601O 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801 Annals of Oncology ·Sapna P. Patel, Hafidh Sholahuddin Zain, Víctor M. Prieto, M. J. S. Lowe, Elizabeth I. Buchbinder, Yuanbin Chen, G. Paul Wright, John Hyngstrom, Naomi Black, Yaya Melsul, Dikri Ramadhan, Kari Kendra, Craig Devoe, Ankit Mangla, Alexandra P. Ikeguchi, Martha Teshome, Larissa A. Korde, James J. Moon, Vernon K. Sondak, L.S .Sathiyamurthy	2025	0
3	Tattooing and risk of melanoma: a population-based case-control study in Utah JNCI Journal of the National Cancer Institute ·Reethajanetsureka Stephensukumaran, Britton Trabert, Lindsay J. Collin, Morgan M. Millar, David Kriebel, Mehdi Khaligi, Mollie E. Barnard, Е. В. Балков, J Kirton, İ. AKAR, Jeffrey A. Gilreath, Douglas Grossman, John Hyngstrom, Paul J. Shami, Jennifer A. Doherty	2025	1
4	The benefit of sentinel lymph node biopsy in elderly patients with melanoma The American Journal of Surgery ·Goro TAKAMORI, Wilton Néri Pereira Júnior, Joshua J. Horns, John Hyngstrom, Tawnya L. Bowles, Douglas Grossman, Elliot A. Asare	2024	2
5	Single-Photon Emission Computed Tomography/Computed Tomography Utilization for Extremity Melanomas at a High-Volume Center Journal of Surgical Research ·M. Stoye, B.A. Jansen-de Graaf, Goro TAKAMORI, Joshua J. Horns, Tawnya L. Bowles, John Hyngstrom, Elliot A. Asare	2024	0
6	Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4⁺ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma Journal for ImmunoTherapy of Cancer ·Magdalena Kovacsovics-Bankowski, Johanna M. Sweere, Haojie Wang, Natalia Sigal, Lichun Cheng, William D. Chronister, Shane A. Evans, 坂戸雅智, Chien-I Chang, Umang Swami, Faraj Jabbar Khalaf, Jordan P. McPherson, Yoko S. DeRose, 金帛張, Carlos Medina, Косиенко Роман Сергеевич, Matthew H. Spitzer, Ngan Luu-Thuy Nguyen, John Hyngstrom, Siwen Hu‐Lieskovan	2024	9
7	A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome Frontiers in Immunology ·坂戸雅智, Jordan P. McPherson, Magdalena Kovacsovics-Bankowski, Joanne Jeter, Christos Vaklavas, Umang Swami, Hal Victor Cartwright, Faraj Jabbar Khalaf, Heloisa P. Soares, Lee 이성희Sung Hee, Chien-I Chang, Jennifer A. Doherty, John Hyngstrom, Sheetal Hardikar, Siwen Hu‐Lieskovan	2023	16
8	Abstract CT053: Merlin_001: a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients Cancer Research ·Tina J. Hieken, Michael E. Egger, Christina V. Angeles, Erin E. Burke, Michael Lowe, John Hyngstrom, Georgia M. Beasley, Edmund K. Bartlett, Vernon K. Sondak	2023	2
9	Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant merkel cell carcinoma and cutaneous squamous cell carcinoma. Journal of Clinical Oncology ·Andrew S. Brohl, Joseph Markowitz, Zeynep Eroglu, Ann W. Silk, John Hyngstrom, Nikhil I. Khushalani, Ahmad A. Tarhini, Shubham Malik, Xueting Jin, Kenneth Y. Tsai, Jacob Thomas	2023	6
10	High dose ipilimumab (Ipi) plus temozolomide (TMZ) after progression on standard or low dose Ipi in advanced melanoma. Journal of Clinical Oncology ·Majid Hussain, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics, Chien-I Chang, Faraj Jabbar Khalaf, Yeong Ran Yun, T.K. Gilmour, Umang Swami, Joanne Jeter, Tawnya L. Bowles, Donald M. Cannon, Ben Haaland, Joyce Schroeder, Jordan P. McPherson, John Hyngstrom, Aik Choon Tan, Siwen Hu‐Lieskovan	2023	1
11	LBA48 Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801 Annals of Oncology ·Sapna P. Patel, Megan Othus, Paul Wright, John Hyngstrom, Christopher D. Lao, Yaya Melsul, Sunandana Chandra, Kari Kendra, Craig Devoe, Aparna Hegde, Ankit Mangla, Michael Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Elad Sharon, Larissa A. Korde, James Moon, Vernon K. Sondak, Antoni Ribas, Víctor G. Prieto	2023	7
12	LBA39 Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL) Annals of Oncology ·R. Dummer, David Gyorki, John Hyngstrom, Rio Valery Allen Allen, Fabielle Sant’ana Volpi, Lev Demidov, Şeyma Bulduk, T. Lawrence, Mark B. Faries, Merrick I. Ross	2022	2
13	Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial Nature Medicine ·Reinhard Dummer, David Gyorki, John Hyngstrom, Adam C. Berger, Robert M. Conry, Lev Demidov, Anjali Sharma, Sheryl Treichel, Hoi-Shen Radcliffe, Kevin Gorski, Abraham Anderson, Emily Chan, Mark B. Faries, Merrick I. Ross	2021	89
14	Trends in the management of anorectal melanoma: A multi-institutional retrospective study and review of the world literature World Journal of Gastroenterology ·Josh Bleicher, Jessica N. Cohan, Lyen C. Huang, Darren Rabinowitz, T. Bartley Pickron, Courtney L. Scaife, Tawnya L. Bowles, John Hyngstrom, Elliot A. Asare	2021	10
15	Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma Melanoma Research ·Alexandra M. Adams, Robert C. Chick, Timothy J. Vreeland, Guy T. Clifton, Diane F. Hale, Patrick M. McCarthy, K. Takahashi, Phillip M. Kemp Bohan, P. Boulin, Molly J. Christians, FM Boffi, John Hyngstrom, Adam C. Berger, James W. Jakub, Jonathan Sussman, Montaser Shaheen, Thomas E. Wagner, Mark B. Faries, George E. Peoples	2021	0
16	Use of the Pigmented Lesion Assay to rapidly screen a patient with numerous clinically atypical pigmented lesions JAAD Case Reports ·Aatman Shah, John Hyngstrom, Scott R. Florell, Douglas Grossman	2019	10
17	Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011) Journal of the American Academy of Dermatology ·Douglas Grossman, James M. Farnham, John Hyngstrom, Hamed Afrasiab, Aaron M. Secrest, Joseph Hussaini Kaltungo, Glen M. Bowen, David A. Wada, Robert H.I. Andtbacka, Kenneth F. Grossmann, Tawnya L. Bowles, Lisa Cannon‐Albright	2018	10
18	Cutaneous carcinosarcoma: a series of six cases and a review of the literature Journal of Cutaneous Pathology ·宮内哲夫, Anneli R. Bowen, Glen M. Bowen, John Hyngstrom, Michael L. Hadley, Keith L. Duffy, Scott R. Florell, David A. Wada	2016	34
19	Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma Melanoma Research ·John Hyngstrom, Yi-Ju Chiang, Kate D. Cromwell, Merrick I. Ross, Yan Xing, 健太郎山際, Jeffrey E. Lee, Jeffrey E. Gershenwald, Richard E. Royal, Anthony Lucci, Jane M. Armer, Janice N. Cormier	2013	38
20	Neoadjuvant strategies for the treatment of locally advanced esophageal cancer Journal of Surgical Oncology ·John Hyngstrom, Mitchell C. Posner	2010	23

About John Hyngstrom

John Hyngstrom is a scholar working on Oncology, Immunology, Complementary and alternative medicine, Biotechnology and Sensory Systems, having authored 68 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (26 papers), CAR-T cell therapy research (24 papers), Cancer Immunotherapy and Biomarkers (22 papers), Immunotherapy and Immune Responses (18 papers), Melanoma and MAPK Pathways (8 papers), Virus-based gene therapy research (6 papers), Cardiovascular and exercise physiology (5 papers) and Cancer Research and Treatments (5 papers). The work is most often cited by research in Oncology (811 citations), Immunology (219 citations), Pathology and Forensic Medicine (159 citations), Complementary and alternative medicine (65 citations) and Surgery (286 citations). John Hyngstrom has collaborated with scholars based in United States, Australia and Switzerland. Frequent co-authors include Robert H.I. Andtbacka, Russell S. Richardson, Barry W. Feig, George J. Chang, Yan Xing, Miguel A. Rodrı́guez-Bigas, Janice N. Cormier, John M. Skibber, Y. Nancy You and Chung-Yuan Hu. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Melanoma Research, Journal of Surgical Oncology and American Journal of Physiology-Heart and Circulatory Physiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact